title: Early-phase development of cancer prevention agents: challenges and opportunities.
abstract: Chemoprevention is the administration of agents (drugs, biologics, dietary supplements, or nutrients) to reduce the risk of developing cancer or prevent the recurrence of cancer. The National Cancer Institute, Division of Cancer Prevention (NCI, DCP), is a major sponsor of cancer preventive preclinical and clinical research. As such, it has developed a comprehensive drug development program specifically designed to meet the requirements needed for cancer preventive drugs to achieve initial regulatory approval. Clinical development of cancer prevention agents presents unique challenges that are not encountered with most cancer therapeutic agents. To meet these challenges, NCI, DCP has implemented new approaches and programs, including phase 0 clinical trial designs and microdose studies. In addition, the PREVENT Cancer Program was recently implemented by NCI, DCP to offer a formalized structure for moving drugs forward in the prevention pipeline using a continue/not continue decision process. Likewise, DCP has implemented a Clinical Trials Consortium to further develop these agents. These and other approaches will be discussed in this commentary.
authors: Division of Cancer Prevention, National Cancer Institute, 6130 Executive Blvd. EPN 2112, Rockville, MD 20892, USA. perloffm@mail.nih.gov
authors: Marjorie
authors: M
authors: Perloff
authors: Vernon E
authors: VE
authors: Steele
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D015195:Drug Design; D006801:Humans; D054547:National Cancer Institute (U.S.); D009369:Neoplasms / Q000517:prevention & control*; D014481:United States
chemical_list: D000970:Antineoplastic Agents